uniQure NV Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
31.3%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$21.4Mnext fiscal year
FY EPS (est.)
-$3.44next fiscal year
Monitoring Framework
Key Performance Indicators
AMT-130 3-Year Clinical Trial Slowing of Disease Progression (cUHDRS) Annually0.8Target: Statistically significant slowing of disease progression compared to external controls
Cash Runway (Years of Funding) Quarterly3.0Target: Sufficient to fund operations into the second half of 2029
Quarterly Revenue (USD Millions) Quarterly3.6Target: Growth in licensing and collaboration revenues
Watch Items
- FDA alignment on confirmatory study design for AMT-130Trigger: Receipt of final Type B meeting minutes or formal protocol agreementAction: Review design requirements to ensure standard-of-care concurrent control is utilized instead of a sham procedure
- UK MHRA Marketing Authorization Application (MAA) submission for AMT-130Trigger: Submission target of Q3 2026Action: Monitor filing completion and subsequent validation by UK regulatory authorities
- U.S. Biologics License Application (BLA) submission for AMT-130Trigger: Submission target of Q3 2026Action: Track preparation of the 3-year clinical data package for accelerated approval filing
Research as of 19 Jun 2026